109 related articles for article (PubMed ID: 6182581)
1. [New antineoplastic agents, their value and use].
Pawlicki M; Zuchowska-Vogelgesang B
Przegl Lek; 1982 Sep; 39(8):561-5. PubMed ID: 6182581
[No Abstract] [Full Text] [Related]
2. [New substances in oncologic therapy].
Cavalli F; Brunner KW
Dtsch Med Wochenschr; 1978 Jul; 103(27):1087-92. PubMed ID: 78789
[No Abstract] [Full Text] [Related]
3. [Chemotherapy in cancers of the colon].
Seitz JF
Gastroenterol Clin Biol; 1993; 17(2 Pt 3):T2-12. PubMed ID: 7686868
[No Abstract] [Full Text] [Related]
4. Investigational drugs under study by the United States National Cancer Institute.
Carter SK; Slavik M
Cancer Treat Rev; 1976 Mar; 3(1):43-60. PubMed ID: 62615
[No Abstract] [Full Text] [Related]
5. [New substances in oncologic therapy].
Cavalli F
Schweiz Med Wochenschr; 1978 Aug; 108(32):1222-7. PubMed ID: 150028
[TBL] [Abstract][Full Text] [Related]
6. Anticancer chemotherapy.
Davey P; Tudhope GR
Br Med J (Clin Res Ed); 1983 Jul; 287(6385):110-3. PubMed ID: 6407699
[No Abstract] [Full Text] [Related]
7. [Chemotherapy of metastasizing cancers of the colon and rectum].
Piedbois P; Lévy E; Le Bourgeois JP; Buyse M
Ann Chir; 1993; 47(6):480-3. PubMed ID: 7692804
[No Abstract] [Full Text] [Related]
8. Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Creech RH; Tritchler D; Ettinger DS; Ferraro JA; Ruckdeschel JC; Vogl SE; Woll J
Cancer Treat Rep; 1984 Sep; 68(9):1183-4. PubMed ID: 6090017
[TBL] [Abstract][Full Text] [Related]
9. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
[No Abstract] [Full Text] [Related]
10. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
[No Abstract] [Full Text] [Related]
12. The emerging role for biomodulation of antineoplastic agents.
Schmoll HJ; Hiddemann W; Rustum Y; Köhne-Wömpner CH
Semin Oncol; 1992 Apr; 19(2 Suppl 3):1-3. PubMed ID: 1557636
[No Abstract] [Full Text] [Related]
13. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
14. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
15. The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen.
Bezwoda WR
Cancer Treat Rev; 1997 Jan; 23(1):17-34. PubMed ID: 9189179
[TBL] [Abstract][Full Text] [Related]
16. Antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids.
Hande KR
Curr Opin Oncol; 1992 Dec; 4(6):1080-8. PubMed ID: 1457522
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Edelman DZ; Anteby SO; Peretz T
Harefuah; 1996 Jul; 131(1-2):31-6. PubMed ID: 8854476
[No Abstract] [Full Text] [Related]
18. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
19. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
[TBL] [Abstract][Full Text] [Related]
20. Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Martin DS; Stolfi RL; Sawyer RC; Young CW
Cancer Treat Rep; 1985 Apr; 69(4):421-3. PubMed ID: 3888389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
